A Phase 3 interventional study of Pemetrexed and Pemetrexed in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-21.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2008, is one of 44 in phase 3, and was the 78th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 939 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 5th largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2008, is one of 25 in phase 3, and was the 63rd registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab
Drug: Pemetrexed · Drug: Carboplatin · Biological: Bevacizumab
Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab
Drug: Paclitaxel · Drug: Carboplatin · Biological: Bevacizumab
Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
Also known as: Alimta, LY231514
Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
Also known as: Alimta, LY231514
Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
Overall Survival
Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
Time frame: Baseline to date of death from any cause (up to 37.06 months)
Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)
Overall Response Rate (ORR) is the number of participants with a Complete Response (CR) and Partial Response (PR) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared to baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions.
Time frame: Baseline to measured progressive disease (up to 37.06 months)
Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate)
Disease Control Rate (DCR) is the number of participants with a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared with baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions compared with the smallest sum of the longest diameter recorded since the start of treatment or the appearance of 1 or more new lesion(s). Stable Disease (SD) was defined as small changes that did not meet above criteria.
Time frame: Baseline to measured progressive disease (up to 37.06 months)
Progression Free Survival Time
Progression free survival (PFS) is defined as the time from date of randomization to the date of objective disease progression or death due to any cause. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.
Time frame: Baseline to measured progressive disease or date of death from any cause (up to 33.54 months)
Time to Progressive Disease
Time to progressive disease was defined as the time from randomization to the first date of objective disease progression. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.
Time frame: Baseline to measured progressive disease (up to 37.06 months)
Safety and Toxicity Profile of Study Treatments
Safety and toxicity profile was defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.
Time frame: Baseline to study endpoint (up to 37.06 months)
Duration of Hospitalizations Per Participant
Length of hospitalization in participants hospitalized during the study or within 30 days of discontinuation regardless of whether the hospitalization was or was not due to study drug.
Time frame: Baseline to study endpoint (up to 37.06 months)
Number of Participants Who Received a Transfusion
Time frame: Baseline to study endpoint (up to 37.06 months)
Number of Participants Receiving Concomitant Medication
Time frame: Baseline to study endpoint (up to 37.06 months)
Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G)
The FACT-G is a validated instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item questionnaire and is organized into subscales, each designed to assess a QOL domain: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-G Total is the sum of the scores of all 4 subscales and ranges from 0 to 108. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.
Time frame: Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)
Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L)
FACT-L is a valid instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item FACT-General (G) and 9-item lung cancer subscale (LCS). FACT-G is organized into subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-L Total Score=4 subscales + LCS and ranges from 0 to 144. Trial Outcome Index-Lung (TOI-L)=PWB+FWB+LCS and ranges from 0 to 92. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.
Time frame: Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)
Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx)
FACT/GOG-Ntx is a validated instrument used to measure quality of life (QOL) in participants with cancer and neurotoxicity (Ntx) consisting of 27-item FACT-General (G) and 11-item Ntx subscale. FACT-G is organized into domain subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items; each uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT/GOG-Ntx Total Score=sum 5 subscales and ranges from 0-152. Ntx Trial Outcome Index (TOI-Ntx)=PWB+FWB+NTX and range from 0-100. For all FACT scales, higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.
Time frame: Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed
Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed
Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed
Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Pharmacokinetics (PK): Pemetrexed Clearance (CL)
Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Total (Bound and Unbound) Platinum and Unbound Platinum
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Total (Bound and Unbound) Platinum and Unbound Platinum
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Total (Bound and Unbound) Platinum and Unbound Platinum
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Pharmacokinetics (PK): Platinum Clearance (CL) for Total (Bound and Unbound) and Unbound Forms
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab
Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab
Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab
Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Pharmacokinetics (PK): Bevacizumab Clearance (CL)
Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Translational Research: Number of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations
Epidermal Growth Factor Receptor (EGFR) mutations were measured by polymerase chain reaction (PCR).
Time frame: Baseline
Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment
Nuclear Thyroid Transcription Factor-1 (TTF-1) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TTF-1 Positive have an H score \>0 and TTF-1 Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
Time frame: Baseline to date of death from any cause (up to 37.06 months)
Translational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression
Cytoplasmic and nuclear Thymidylate Synthase (TS) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic and nuclear staining, and H score was calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TS Positive have an H score \>0 and TS Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
Time frame: Baseline to date of death from any cause (up to 37.06 months)
Translational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression
Cytoplasmic and membrane Folate Receptor Alpha (FR-α) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic or membrane staining, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). FR-α Positive have an H score \>0 and FR-α Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
Time frame: Baseline to date of death from any cause (up to 37.06 months)
| Milestone | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Started | 472 | 467 |
| Received at least 1 dose of study drug | 442 | 443 |
| Completed | 294 | 298 |
| Not completed | 178 | 169 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Entry criterion not met | 12 | 11 |
| Withdrew: Adverse event | 27 | 38 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Progressive disease | 73 | 55 |
| Withdrew: Physician decision | 21 | 20 |
| Withdrew: Withdrawal by subject | 15 | 19 |
| Withdrew: Deaths not due to study disease | 19 | 14 |
| Withdrew: Deaths due to study disease | 9 | 9 |
| Milestone | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Started | 294 | 298 |
| Received at least 1 dose of study drug | 294 | 298 |
| Completed | 0 | 0 |
| Not completed | 294 | 298 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Entry criterion not met | 0 | 2 |
| Withdrew: Adverse event | 42 | 26 |
| Withdrew: Progressive disease | 186 | 224 |
| Withdrew: Physician decision | 25 | 20 |
| Withdrew: Withdrawal by subject | 34 | 14 |
| Withdrew: Death not due to study disease | 2 | 5 |
| Withdrew: Death due to study disease | 3 | 3 |
| Withdrew: Other | 1 | 1 |
Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
| months | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Overall Survival | 12.55 (11.30 to 14.03) | 13.40 (11.86 to 14.91) |
Overall Response Rate (ORR) is the number of participants with a Complete Response (CR) and Partial Response (PR) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared to baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions.
| percentage of participants | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate) | 34.1 (29.8 to 38.6) | 33.0 (28.7 to 37.4) |
Disease Control Rate (DCR) is the number of participants with a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared with baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions compared with the smallest sum of the longest diameter recorded since the start of treatment or the appearance of 1 or more new lesion(s). Stable Disease (SD) was defined as small changes that did not meet above criteria.
| percentage of participants | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate) | 65.9 (61.4 to 70.2) | 69.8 (65.4 to 73.9) |
Progression free survival (PFS) is defined as the time from date of randomization to the date of objective disease progression or death due to any cause. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.
| months | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Progression Free Survival Time | 6.04 (5.55 to 6.87) | 5.55 (5.39 to 5.98) |
Time to progressive disease was defined as the time from randomization to the first date of objective disease progression. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.
| months | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Time to Progressive Disease | 7.03 (6.24 to 8.05) | 6.04 (5.58 to 6.87) |
Safety and toxicity profile was defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.
| participants | Pem/Carbo/Bev; Induction Phase | Pem/Carbo/Bev; Maintenance Phase | Pac/Carbo/Bev; Induction Phase | Pac/Carbo/Bev; Maintenance Phase |
|---|---|---|---|---|
| Serious Adverse Events (SAEs) | 111 | 83 | 123 | 68 |
| Other Adverse Events (AEs) | 432 | 288 | 431 | 296 |
Length of hospitalization in participants hospitalized during the study or within 30 days of discontinuation regardless of whether the hospitalization was or was not due to study drug.
| days | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Duration of Hospitalizations Per Participant | 9.4 ± 9.8 | 8.0 ± 6.7 |
| participants | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Number of Participants Who Received a Transfusion | 116 | 44 |
| participants | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Number of Participants Receiving Concomitant Medication | 406 | 421 |
The FACT-G is a validated instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item questionnaire and is organized into subscales, each designed to assess a QOL domain: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-G Total is the sum of the scores of all 4 subscales and ranges from 0 to 108. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.
| units on a scale | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G) | 0.51 ± 0.54 | 0.18 ± 0.54 |
FACT-L is a valid instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item FACT-General (G) and 9-item lung cancer subscale (LCS). FACT-G is organized into subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-L Total Score=4 subscales + LCS and ranges from 0 to 144. Trial Outcome Index-Lung (TOI-L)=PWB+FWB+LCS and ranges from 0 to 92. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.
| units on a scale | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| FACT-L Total Score (n=397, 392) | 1.88 ± 0.65 | 1.66 ± 0.66 |
| Trial Outcome Index-Lung (TOI-L) (n=396, 394) | -0.38 ± 0.50 | -0.40 ± 0.50 |
FACT/GOG-Ntx is a validated instrument used to measure quality of life (QOL) in participants with cancer and neurotoxicity (Ntx) consisting of 27-item FACT-General (G) and 11-item Ntx subscale. FACT-G is organized into domain subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items; each uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT/GOG-Ntx Total Score=sum 5 subscales and ranges from 0-152. Ntx Trial Outcome Index (TOI-Ntx)=PWB+FWB+NTX and range from 0-100. For all FACT scales, higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.
| units on a scale | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| FACT/GOG-Ntx Total Score (n=393, 389) | -0.60 ± 0.70 | -5.48 ± 0.70 |
| Ntx Trial Outcome Index (TOI-Ntx)(n=393, 390) | -2.79 ± 0.55 | -7.60 ± 0.55 |
| micrograms per milliliter (μg/mL) | Pem/Carbo/Bev |
|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed | 122 ± 20 |
| hours (hr) | Pem/Carbo/Bev |
|---|---|
| Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed | 2.88 ± 13 |
| microgram*hour per milliliter (μg•hr/mL) | Pem/Carbo/Bev |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed | 203 ± 23 |
| milliliters per minute (mL/min) | Pem/Carbo/Bev |
|---|---|
| Pharmacokinetics (PK): Pemetrexed Clearance (CL) | 72.1 ± 25 |
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
| micrograms per milliliter (μg/mL) | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Total (Bound and Unbound) | 18.4 ± 24 | 17.8 ± 33 |
| Unbound (n=18, 15) | 21.1 ± 31 | 17.1 ± 34 |
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
| hours (hr) | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Total (Bound and Unbound) | 65.6 ± 69 | 86.4 ± 21 |
| Unbound (n=17, 13) | 2.03 ± 15 | 1.95 ± 21 |
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
| microgram*hour per milliliter (μg•hr/mL) | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Total (Bound and Unbound) | 160 ± 32 | 182 ± 24 |
| Unbound (n=17, 13) | 55.7 ± 33 | 62.9 ± 34 |
Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.
| liters per hour (L/hr) | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Total (Bound and Unbound) | 2.02 ± 39 | 1.87 ± 28 |
| Unbound (n=17, 13) | 5.81 ± 35 | 5.36 ± 47 |
| micrograms per milliliter (μg/mL) | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab | 276 ± 18 | 302 ± 20 |
| days | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab | 14.8 ± 36 | 12.8 ± 46 |
| microgram*day per milliliter (μg•day/mL) | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab | 3070 ± 29 | 3160 ± 33 |
| liters per day (L/day) | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| Pharmacokinetics (PK): Bevacizumab Clearance (CL) | 0.341 ± 31 | 0.376 ± 38 |
Epidermal Growth Factor Receptor (EGFR) mutations were measured by polymerase chain reaction (PCR).
| participants | Pem or Pac Plus Carbo/Bev |
|---|---|
| EGFR mutation positive | 11 |
| EGFR mutation negative | 121 |
Nuclear Thyroid Transcription Factor-1 (TTF-1) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TTF-1 Positive have an H score \>0 and TTF-1 Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
| months | TTF-1 Positive (H Score > 0) | TTF-1 Negative (H Score = 0) |
|---|---|---|
| Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment | 14.9 (12.8 to 17.6) | 8.7 (6.4 to 10.5) |
Cytoplasmic and nuclear Thymidylate Synthase (TS) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic and nuclear staining, and H score was calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TS Positive have an H score \>0 and TS Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
| months | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| TS Cytoplasm Positive (H score > 0; n=90, 83) | 12.9 (10.8 to 16.9) | 12.4 (10.9 to 15.5) |
| TS Cytoplasm Negative (H score = 0; n=10, 6) | 18.2 (12.5 to NA) | 11.6 (9.1 to 14.7) |
| TS Nucleus Positive (H score > 0; n=68, 51) | 12.7 (9.7 to 15.4) | 12.4 (8.4 to 15.5) |
| TS Nucleus Negative (H score = 0; n=32, 38) | 19.2 (12.5 to 24.1) | 12.4 (10.1 to 17.1) |
Cytoplasmic and membrane Folate Receptor Alpha (FR-α) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic or membrane staining, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). FR-α Positive have an H score \>0 and FR-α Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.
| months | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| FR-α Cytoplasm Positive (H score > 0; n=64, 53) | 14.4 (11.4 to 22.2) | 14.3 (11.2 to 18.2) |
| FR-α Cytoplasm Negative (H score = 0; n=34, 29) | 12.0 (9.6 to 16.9) | 11.2 (5.7 to 14.4) |
| FR-α Membrane Positive (H score > 0; n=39, 22) | 19.2 (10.5 to 30.8) | 15.5 (11.2 to NA) |
| FR-α Membrane Negative (H score = 0; n=59, 60) | 12.9 (9.6 to 16.7) | 11.3 (8.8 to 14.7) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pem/Carbo/Bev | — | 188/442 (42.5%) | 430/442 (97.3%) |
| Pac/Carbo/Bev | — | 181/443 (40.9%) | 433/443 (97.7%) |
| Event | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| PneumoniaInfections and infestations | 28/442 | 27/443 |
| DehydrationMetabolism and nutrition disorders | 20/442 | 21/443 |
| AnaemiaBlood and lymphatic system disorders | 18/442 | 5/443 |
| Deep vein thrombosisVascular disorders | 5/442 | 14/443 |
| VomitingGastrointestinal disorders | 13/442 | 11/443 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/442 | 13/443 |
| ThrombocytopeniaBlood and lymphatic system disorders | 12/442 | 3/443 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 11/442 | 4/443 |
| NauseaGastrointestinal disorders | 9/442 | 11/443 |
| NeutropeniaBlood and lymphatic system disorders | 10/442 | 9/443 |
| Event | Pem/Carbo/Bev | Pac/Carbo/Bev |
|---|---|---|
| FatigueGeneral disorders | 268/442 | 257/443 |
| NauseaGastrointestinal disorders | 236/442 | 223/443 |
| NeutropeniaBlood and lymphatic system disorders | 170/442 | 219/443 |
| AlopeciaSkin and subcutaneous tissue disorders | 34/442 | 193/443 |
| ConstipationGastrointestinal disorders | 181/442 | 166/443 |
| AnaemiaBlood and lymphatic system disorders | 177/442 | 136/443 |
| ThrombocytopeniaBlood and lymphatic system disorders | 159/442 | 105/443 |
| Decreased appetiteMetabolism and nutrition disorders | 133/442 | 145/443 |
| Neuropathy peripheralNervous system disorders | 42/442 | 145/443 |
| DiarrhoeaGastrointestinal disorders | 100/442 | 118/443 |
All randomized participants.
| Age, Customized(participants) | Pem/Carbo/Bev | Pac/Carbo/Bev | Total |
|---|---|---|---|
| <=65 years | 249 | 236 | 485 |
| >65 years | 223 | 231 | 454 |
| Sex: Female, Male(Participants) | Pem/Carbo/Bev | Pac/Carbo/Bev | Total |
|---|---|---|---|
| Female | 221 | 218 | 439 |
| Male | 251 | 249 | 500 |
| Race/Ethnicity, Customized(participants) | Pem/Carbo/Bev | Pac/Carbo/Bev | Total |
|---|---|---|---|
| Caucasian | 409 | 396 | 805 |
| Black or African American | 42 | 52 | 94 |
| Asian | 15 | 14 | 29 |
| American Indian or Alaska Native | 1 | 1 | 2 |
| Multiple race/ethnicities | 2 | 3 | 5 |
| Information not provided | 3 | 1 | 4 |
| Region of Enrollment(participants) | Pem/Carbo/Bev | Pac/Carbo/Bev | Total |
|---|---|---|---|
| United States | 472 | 467 | 939 |
| Previously Treated Brain Metastasis(participants) | Pem/Carbo/Bev | Pac/Carbo/Bev | Total |
|---|---|---|---|
| Yes | 52 | 52 | 104 |
| No | 420 | 415 | 835 |
| Histological Subtype(participants) | Pem/Carbo/Bev | Pac/Carbo/Bev | Total |
|---|---|---|---|
| Adenocarcinoma, Lung | 367 | 360 | 727 |
| Bronchioalveolar Carcinoma | 4 | 3 | 7 |
| Large Cell Lung Carcinoma | 8 | 15 | 23 |
| NSCLC Not Otherwise Specified | 47 | 39 | 86 |
| NSCLC Poorly Differentiated | 39 | 47 | 86 |
| Predominantly Adenocarcinoma | 7 | 2 | 9 |
| Unknown | 0 | 1 | 1 |
| Histological Category for Subgroup Analyses(participants) | Pem/Carbo/Bev | Pac/Carbo/Bev | Total |
|---|---|---|---|
| Adenocarcinoma | 378 | 365 | 743 |
| Large Cell Carcinoma | 8 | 15 | 23 |
| Other or Indeterminant | 86 | 86 | 172 |
| Unknown | 0 | 1 | 1 |
The record gives a start of Dec 2008, a primary completion of Apr 2012 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →